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(e pituitary hormone, thyrotropin (TSH), is regarded as the primary biomarker for evaluating thyroid function and is useful in
guiding treatment with levothyroxine for patients with hypothyroidism. (e amplified response of TSH to slight changes in
thyroid hormone levels provides a large and easily measured signal in the routine care setting. Laboratories provide reference
ranges with upper and lower cutoffs for TSH to define normal thyroid function. (e upper limit of the range, used to diagnose
subclinical (mild) hypothyroidism, is itself a matter for debate, with authoritative guidelines recommending treatment to within
the lower half of the range. Concomitant diseases, medications, supplements, age, gender, ethnicity, iodine status, time of day,
time of year, autoantibodies, heterophilic antibodies, smoking, and other factors influence the level of TSH, or the performance of
current TSH assays. (e long-term prognostic implications of small deviations of TSH from the reference range are unclear.
Correction of TSH to within the reference range does not always bring thyroid and other biomarkers into range and will not
always resolve the patient’s symptoms. Overt hypothyroidism requires intervention with levothyroxine. It remains important that
physicians managing a patient with symptoms suggestive of thyroid disease consider all of the patient’s relevant disease, lifestyle,
and other factors before intervening on the basis of a marginally raised TSH level alone. Finally, these limitations of TSH testing
mitigate against screening the population for the undoubtedly substantial prevalence of undiagnosed thyroid disease, until
appropriately designed randomised trials have quantified the benefits and harms from this approach.
1. Introduction
(e prevalence of treated hypothyroidism is increasing in
both the United Kingdom and the United States [1, 2].
Furthermore, the global prevalence of undiagnosed thyroid
dysfunction, at least in the developed world, is falling,
probably due to a combination of iodine supplementation in
iodine-deficient areas, widespread and frequent thyroid
function assessment, and lower thresholds to commence
treatment [3–5]. Approximately, 1–3% of the population has
hypothyroidism in iodine-replete areas, with much higher
prevalence in older persons and in women [5, 6].
(e symptoms of thyroid dysfunction are often non-
specific, and diagnosis is confirmed by laboratory tests for
thyroid hormones and the pituitary hormone thyrotropin
(TSH). Current guidelines for the diagnosis and manage-
ment of thyroid dysfunction focus primarily on the mea-
surement of TSH, as the most sensitive and specific marker
of systemic thyroid status, with test results interpreted
according to defined reference ranges [7–9]. However,
serum TSH has several limitations, and “normal” levels are
not necessarily indicative of tissue-specific thyroid hor-
mone status. (e purpose of our review is to summarise the
evidence-based rationale for current thyroid testing
practices and to address common pitfalls in the in-
terpretation of challenging results. Furthermore, it is im-
portant to remember that TSH is a pituitary hormone and
ensuring normal pituitary function is vital prior to inter-
preting its circulating levels and its relationship with
thyroid hormones.
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2. Overview of TSH and Relationship with
Thyroid Hormones
(e physiology of thyroid hormone regulation has been
reviewed extensively elsewhere [10, 11]. Accordingly, only a
brief account will be given here, focussing on those aspects of
the hypothalamus-pituitary-thyroid axis that are most rel-
evant to the design and use of thyroid function tests. (e
regulation of thyroid hormone secretion is conducted from
within the central nervous system, which allows modulation
of the system from periphery, via feedback from nutrient
intake or via the autonomic nervous system [11]. In brief,
thyrotropin-releasing hormone (TRH) is secreted from the
hypothalamus and reaches the anterior pituitary via the
hypophyseal portal circulation. Activation of TRH receptors
stimulates the release of TSH, which activates its own re-
ceptors on the follicular cells of the thyroid gland. (is
causes increased cellular uptake of iodine from the blood,
increased synthesis of thyroglobulin, and secretion into the
blood stream of triiodothyronine (T3) and thyroxine (T4)
via activation of the enzyme thyroid peroxidase (TPO).
Feedback circuits result in an inverse relationship be-
tween serum levels of thyroid hormones and TSH, i.e., low
T4 (as observed in hypothyroidism) and high T4 (as seen in
hyperthyroidism) levels are associated with elevated and low
TSH, respectively. (e relationship between the magnitude
of changes in serum TSH and the resulting magnitude of
changes in circulating thyroid hormones is the key aspect of
the regulation of thyroid function with regard to diagnosis of
thyroid disorders. (e precise nature of the relationship
remains under debate, but the relationship between TSH and
T4 approximates to an inverse log-linear relationship for
most individuals, and this relationship becomes clearer for a
given individual when more data points are available to
define it [12–14].
Importantly, a halving of circulating T4 is accompanied
by up to a 100-fold increase in serum TSH. Furthermore, the
relationship between TSH and T4 varies amongst in-
dividuals and is affected, amongst other factors, by age,
smoking, levothyroxine treatment, and the presence of
antibodies [12, 15, 16]. Clearly, these large alterations in TSH
are more amenable to identification by routine measure-
ments in clinical laboratories than small variations in T4,
and this explains the use of TSH measurements as the gold
standard for the diagnosis of thyroid disorders in current
guidelines for the management of hypothyroidism [7, 9].
3. Serum TSH as the Principal Diagnostic
Marker of Systemic Thyroid Status
3.1. Evolution of the TSH Test. Prior to the development of
TSH and thyroid hormone testing in serum, other biological
markers of thyroid hormone status such as basal metabolic
rate were used to diagnose thyroid dysfunction and also to
titrate thyroid hormone replacement doses [17]. Testing for
thyroid function began in the 1950s with the development of
an indirect test for total T4 [18]. Since then, continual de-
velopment of radioimmuno- and liquid chromatography-
tandem mass spectrometry-based assay technology has led
to the availability to physicians in the routine care setting of
accurate and precise measurement of TSH, T4, T3, thyroid
hormone-binding proteins, thyroglobulin, and various au-
toantibodies of diagnostic interest [18]. Quantitative mea-
surements of serum TSH by radioimmunoassay were first
reported by Utiger [19]. (e early TSH assays had a limit of
detection of approximately 1mIU/L, which was sufficient to
diagnose primary hypothyroidism [7, 9]. Increases in the
sensitivity of TSH tests were driven by the need to quantify
much lower TSH levels associated with the diagnosis of
hyperthyroidism, particularly the subclinical form.
Interpretation of a biomarker test result depends on the
ability to distinguish normal from abnormal. (e population
reference range for “normal” TSH is defined as containing 95%
of a “normal” population who are believed to be free of
conditions that could influence TSH levels, with 2.5% of
subjects above and below the range [7]. Reference ranges may
be device-, laboratory-, and population-specific, and “normal”
or “abnormal” results may be diagnosed using reference ranges
from populations local to the laboratory [20].
Guidelines cite a reference and therapeutic target range
for TSH to define normal thyroid function in adults at
0.4–4.0mIU/mL [9]. Subclinical hypothyroidism is defined
as TSH above the reference and when thyroid hormone
levels are normal; conversely, subclinical hyperthyroidism is
characterised by T4 and T3 within the normal range and low
TSH. In most laboratories, measurement of FT4 only occurs
when TSH is out of range. A large observational study from
Australia showed that restricting free T4 (FT4) measure-
ments to patients whose serum TSH was clearly outside its
reference range (<0.2mIU/L or >6mIU/L) had little or no
impact on the diagnostic utility of the TSH test [21].
(e management of overt thyroid dysfunction is not
disputed, and there is widespread agreement that this con-
dition should be treated [8, 9].(e question remains as to how
to proceed in the case of a borderline TSH test. Current
European guidelines recommend a trial of levothyroxine
treatment for younger patients (<65–70 y) with symptoms
reminiscent of hypothyroidism and mildly elevated TSH
(<10mU/L) [22]. Larger elevations of TSH in these younger
patients require treatment with levothyroxine irrespective of
the presence or absence of symptoms [22]. A strategy of
watchful waiting is appropriate for very elderly patients, with
use of levothyroxine where clearly necessary [22].
3.2. Limitations of TSH as a Diagnostic Marker of 2yroid
Function. (e introduction of cutoff values for TSH renders
the diagnosis of thyroid disease categorical, in that even a
small increase in TSH can in principle lead to the patient
potentially acquiring the lifelong label of a medical condi-
tion. A number of demographic, diagnostic, and disease-
related factors, described briefly below, influence the TSH
level and should be considered whenmaking the diagnosis of
hypothyroidism (Figure 1).
3.2.1. Age and Gender. A study in a population of about
150,000 thyroid antibody-negative people, without the
history of treatment for a thyroid-related condition, found
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that the 97.5th percentile for TSH (i.e., the upper limit for a
TSH reference range in this population) increased from
3.98mIU/L at age 31–40 to 5.94mIU/L at age >90 years [20].
Increasing TSH with age was observed for both men and
women in this study, while this and other studies have
demonstrated higher levels of TSH in women than in men
[14, 20, 23, 24]. A representative survey in Korea found the
lowest TSH levels in middle-aged individuals, with higher
values in younger and older age groups [23]. (e effect of
TSH on the rate of conversion of FT4 to FT3 is age-de-
pendent, with increasing FT3/FT4 ratios seen as TSH in-
creases, at least up to middle age [15]. (e response of TSH
levels to hypothyroidism may be larger in younger subjects
[12]. (ese data support the use of locally derived, age-
specific, and gender-specific reference ranges for TSH.
3.2.2. Ethnicity. A study from a large, nationally representa-
tive, population-based cohort in the USA found higher levels of
TSH in non-Hispanic white vs. non-Hispanic black orMexican
American subjects [24]. A high titre of thyroid autoantibodies is
also less prevalent in black vs. white subjects in this study. Data
from Brazil demonstrated a lower prevalence of hypothyroid-
ism (but more hyperthyroidism) in black subjects vs. other
ethnicities [25]. Ethnicity also influences thyroid hormone
levels, which could produce an aberrant test where the local
population that supplied subjects for determining the reference
range is mainly of a different ethnicity to the patient [26].
3.2.3. Medications and Supplements. Numerous concurrent
medications and supplements can interfere with thyroid
function tests (summarised in Figure 1) [27, 28]. Metformin,
the most commonly prescribed pharmacologic treatment for
type 2 diabetes, reduces TSH with no change in FT4 in
treated or untreated hypothyroid patients [29] or in patients
with benign thyroid nodules [30]. A meta-analysis showed
that metformin treatment reduced TSH levels in patients
with overt, levothyroxine-treated hypothyroid disease, or
subjects with untreated subclinical hypothyroidism, but not
in euthyroid individuals [31]. Another study, however,
concluded that metformin treatment reduces serum TSH
levels that are towards the upper limit of the reference range
independent of anti-thyroid antibody status [32]. Amio-
darone may induce a transient or sustained hypothyroid-like
condition (increased TSH) or thyroiditis (decreased TSH).
Alemtuzumab, proton pump inhibitors, antiepileptic drugs,
glucocorticoids, rexinoids, dopamine agonists, somatostatin
analogues, interferon-α, and tyrosine kinase inhibitors are
among other drugs known to alter TSH levels [27]. Dietary
iodide supplements increase the TSH activity, and variations
in local iodide intake may affect TSH reference ranges [28].
Dietary soya and supplements, such as those containing
calcium or iron, may interfere with the absorption of lev-
othyroxine and thus increase TSH [33].
3.2.4. Interference with Assays. Automated immunoassays
are vulnerable to interference that can affect thyroid func-
tion results and thus have impact on clinical decision
making. It is estimated that interference is prevalent in al-
most 1% of all thyroid function tests, and therefore, the scale
of the problem is potentially enormous. Interference with
thyroid function tests should be suspected when the result is
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Figure 1: Overview of common factors that can produce an aberrant TSH test. aMetformin reduces serum TSH in people with overt or
subclinical hypothyroidism and in euthyroid individuals with high normal baseline TSH levels (see refs [31] and [32]; see text for other
references). HAMA: human anti-mouse antibody; RF: rheumatoid factor; TSH: thyrotropin.
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discordant with the clinical or other biochemical findings
[27]. People with hypothyroidism may produce a form of
TSH, “macro-TSH,” made up of TSH coupled with IgG
autoantibodies, which may be recognised to different extents
by different commercial assays for TSH [34]. (is may
provide another potentially important source of both
interpatient variation and discordance between the reported
TSH level and the individual patient’s clinical thyroid status.
Finally, a “sandwich” immunoassay-based TSH test may
use non-human antibodies directed against TSH, where
immobilised antibodies capture TSH in the sample, and
antibodies directed against other TSH epitopes generate the
assay signal. A patient’s serum may contain heterophilic
antibodies, which are antibodies directed against animal
antibodies of the same species used in the assay.(ese human
anti-animal antibodies may bridge between the capture and
detection of antibodies in the assay and generate a false
positive signal, leading to a falsely elevated TSHmeasurement
[27, 35]. Human anti-mouse antibody (HAMA) is the most
common heterophilic antibody, among others. Assays con-
tain defences against heterophilic antibodies, although these
may be overwhelmed if the interfering antibody is present at a
high enough titre. Rheumatoid factors (RF), IgM species
directed against human IgG, are present in patients with
autoimmune diseases, particularly rheumatoid arthritis [35].
RF acts like HAMA by binding to antibodies used in the TSH
assay and thus altering the test result. Biotin, antistreptavidin
antibodies, antiruthenium antibodies, and thyroid hormone
autoantibodies provide other sources of interference with the
TSH test that may lead to an aberrant result [36].
3.2.5. Individual “Set Points” for 2yroid Hormones and Risk
of End-Organ Damage. Diagnostic reference ranges are, by
definition, a one-size-fits-all solution to the challenge of
interpreting biomarker results [37]. Longitudinal mea-
surement of thyroid hormones in healthy individuals has
shown that levels of T3, T4, and FT4 index vary little over
time [38]. Each individual appears to have his/her own,
unique relationship between TSH and T3 or T4, which is
partly genetically determined [39] and influenced relatively
little by biological variation [40]. By implication, TSH may
reflect the characteristics of the individual’s hypothalamic-
pituitary-thyroid axis as much as it reflects a holistic estimate
of metabolic function.
A TSH value slightly above or below the reference range
(with other thyroid hormones within their ranges) might be
appropriate for this individual but could nevertheless pre-
cipitate a diagnosis of subclinical thyroid disease. One
proposal has been to define quantitatively each patient’s
unique euthyroid set point to guide management [41]. (is
approach may prove to be both cumbersome and expensive.
Treatment with levothyroxine has been shown to influence
an individual’s set point for thyroid function, with higher
FT4 and lower FT3, despite a lower TSH level compared
with untreated patients [42]. An alternative approach could
be to define optimal ranges for TSH and FT4 based on risk
engine-derived estimates of the risk of adverse cardiovas-
cular outcomes, in a manner analogous to that used for
setting treatment goals in the management of serum lipids
[43].
3.2.6. Diurnal and Circannual Variations in TSH Levels.
A diurnal variation exists for TSH levels in euthyroid and
hypothyroid patients (treated or untreated), with lower
values in the daytime [44, 45]. (e magnitude of the cir-
cadian rhythm in TSH is greater for older people due to a
larger increase in nocturnal TSH production, and the cir-
cadian rhythms for TSH have been observed to differ
according to ethnicity [46]. (e nadir in TSH levels occurs
around the middle of the day [44] so that the daytime
sampling of blood for TSH measurements should minimise
the interference with the test from this source. A circannual
variation for TSH has been reported with lower values
recorded in the summer [47], although another study re-
ported no change in the TSH reference range at different
times of the year [46].
3.2.7. Pregnancy. (e size of the thyroid gland, thyroid
hormone production, and iodine requirements all increase
markedly during pregnancy, with a concomitant fall in the
TSH level. Current guidelines for the management of thy-
roid disease accept the need for a lower upper limit of the
reference range during different stages of pregnancy, but
differences between populations in the magnitude of the
effect of pregnancy on thyroid hormone levels have been
observed [8, 48]. Accordingly, these guidelines stress the
need for locally derived reference ranges for the manage-
ment of pregnant women.
3.2.8. Obesity. (ere appears to be a functional in-
terrelationship between adiposity and thyroid status, in
which TSH levels are correlated positively with body mass
index [49]. TSH is reduced in obese patients who have
undergone bariatric surgery, with little effect on T4 levels,
consistent with a mechanism by which increased leptin
levels drive increased TSH secretion in the setting of obesity
[50]. Morbid obesity, in particular, leads to an isolated in-
crease in serum TSH levels without any role for thyroid
autoimmunity [49].
3.2.9. Methodological Issues Relating to the Calculation of
Reference Ranges. Recruiting a truly “normal” population
for defining a reference range for TSH is challenging. Evi-
dence from the US National Health and Nutrition Exami-
nation Survey (NHANES) found that about 4% of a
population of community-dwelling subjects who were
nominally free of thyroid dysfunction had evidence of occult
autoimmune thyroid disease that increased the median TSH
level and the upper reference limit for TSH [24, 51]. In
another study, the use of sonography to detect and exclude
people with thyroid abnormalities from a “healthy” refer-
ence population led to a lower reference range compared
with the original group before these exclusions [52]. Other
data have suggested limited benefit from adding sonography
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to the screening procedure for a TSH reference population,
however [52–55].
Such observations have led for calls for the upper ref-
erence limit for TSH to be reduced, based on an observation
that >95% of truly euthyroid patients have TSH <2.5mIU/L
and people with higher values were likely to have Hashi-
moto’s thyroiditis or other conditions that increase TSH
[56]. An alternative argument accepts that a substantial
proportion of people in the upper part of the TSH reference
range will indeed have some form of occult thyroid disease
but with a sufficiently benign prognosis that it is unnecessary
to alter reference ranges to reclassify these by defining
healthy people as thyroid patients [57]. Guidance from the
UK National Institute for Health and Care Excellence
(NICE) recommends controlling TSH to the lower half of
the reference range (0.4–2.5mIU/L) for most people with
subclinical hypothyroidism who require treatment [8].
Mathematical manipulation of TSH levels from a healthy
TSH reference population is needed to define the TSH
reference range, and precisely how this is done can lead to
differences in the calculated reference values that are large
enough to be clinically significant [58]. Data from 271
healthy control subjects and 820 patients with various forms
of thyroid disease showed that different statistical methods
used for derivation of the reference range could result in
different classifications of the thyroid status for as many as
12% of the patients [59].
3.2.10. Smoking. A recent analysis from the Korean National
Health and Examination Survey evaluated associations be-
tween urinary cotinine (a metabolite of nicotine used rou-
tinely to assess exposure to tobacco) and thyroid function
[60]. (ere was no significant association between FT4 and
urinary cotinine, but TSH was correlated negatively with the
cotinine levels in men and women, and levels of anti-TPO
antibodies correlated positively with cotinine in men. (ese
data confirm earlier reports of reduced TSH levels in
smokers vs. nonsmokers [16].
3.2.11. Variation in TSH Levels over Time. (e diagnosis of
subclinical hypothyroidism is categorical, as described
above, so that small variations around the upper reference
range for TSH can contribute to confirming or excluding the
diagnosis of this condition. It is important to note that small
increases in TSH above a stated reference range may resolve
spontaneously. (is was observed in an observational study
where 37/40 people with subclinical hypothyroidism (de-
fined as TSH >5mIU/L) reverted to normal TSH level (by
this definition) over a follow-up period of 5 years, with most
reverting to a TSH level below this cutoff early in the follow-
up period [61].
3.2.12. Endocrine Disruptors. A growing literature is asso-
ciating accumulation in the biosphere of a range of chem-
icals with alterations in numerous physiological functions,
including the thyroid gland. Endocrine disruptors shown to
influence thyroid function include a number of chemicals
that are widely distributed in the environment, such as
industrial chemicals used in the manufacture of plastics,
flame retardants, fertilisers, and pesticides, among others
[62]. (e results of studies of endocrine disruptors on
thyroid function have been conflicting to date, and thyroid
hormone levels can be increased or decreased by exposure to
these substances [62]. Importantly, early exposure to these
substances may promote permanent changes in the regu-
lation of the thyroid system [63, 64]. A recent commentary
concluded that we are not ready to develop guidelines in this
area, due to a lack of consistently designed studies, in-
terregional and intersubject variability in the effects ob-
served, and difficulty in estimating exposure [62]. (e
ubiquity of potential endocrine disruptors in the environ-
ment, and growing evidence of harm associated with them,
identifies this area as important for the future in multiple
fields of medicine.
4. Population Screening for Thyroid
Dysfunction: We Can, but Should We?
Neonatal screening for congenital hypothyroidism (based on
the measurement of TSH levels) is practised in many
countries and is supported by guidelines [65].(ere is less of
a consensus regarding screening of the population for un-
diagnosed thyroid disease, which may be common among
the general population. For example, about 6% of subjects in
the NHANES III cohort in the USA had evidence of un-
diagnosed thyroid disease [24]. A meta-analysis of studies
from Europe found a high prevalence of undiagnosed hy-
pothyroidism of about 5% and of undiagnosed hyperthy-
roidism of about 2% [5]. Similarly, previously undiagnosed
thyroid disease was found in an iodine-deficient area of
Germany ten years following the introduction of iodine
supplementation (subclinical hypothyroidism 0.5%; overt
hypothyroidism 0.7%; subclinical hyperthyroidism 1.8%;
overt hyperthyroidism 0.4%) [4].
Current TSH tests are reliable, automated, and suitable
for routine use, provided that clinicians are aware of their
limitations. (e universal availability of routine TSH testing
could render screening for primary thyroid disease, a re-
alistic possibility. (e introduction of population screening
would require good evidence of the benefits and harms that
would be expected to arise from the programme. A sys-
tematic review of studies that evaluated screening for the
thyroid disease in the primary care setting in 1998 concluded
that opportunistic screening of women aged >50 years may
be beneficial but again called for large, randomised trials to
validate the use of population screening for subclinical
hypothyroidism [66]. Another systematic review of studies
in this area (2003) concluded that the case for population
screening for thyroid disorders was weak, when assessed
against the current evidence base [67]. (e current (2015)
position of the US government concluded that there was still
insufficient evidence to support population screening for
thyroid dysfunction in nonpregnant, asymptomatic adults
[68].
Population screening for thyroid disease remains an in-
triguing proposition. Randomised controlled trials to clarify
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optimal strategies for screening and intervention may be
required before it becomes a practicable proposition, espe-
cially for detecting undiagnosed subclinical hypothyroidism.
5. Conclusions
TSH is the primary biomarker for the diagnosis of thyroid
dysfunction and for guiding treatment of thyroid disease.
(e provision of clear and unambiguous laboratory refer-
ence ranges for “normal” TSH conceals a number of im-
portant caveats that should be remembered when using a
TSH test for diagnosis. For the diagnosis of hypothyroidism,
the upper cutoff for TSH that best predicts prognosis re-
mains uncertain, and multiple demographic, laboratory, and
disease characteristics interfere with the TSH test. It is
important to manage the whole patient, considering these
limitations, rather than treating solely on the basis of a
slightly elevated TSH test result. In future, individually based
TSH reference ranges, or optimal TSH levels based on
prediction of adverse cardiovascular outcomes, may be
useful in identifying many people with undiagnosed thyroid
disease, although we do not have a sufficient evidence base
for this approach at present. Furthermore, there is a pressing
need to identify easily measurable biomarkers of tissue
thyroid hormone status.
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